Meeting
2021 ASCO Annual Meeting
Racial differences and trends in pathologic complete response following neoadjuvant chemotherapy for breast cancer.
Authors
Sung Jun Ma
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Sung Jun Ma , Brian Yu , Lucas M Serra , Austin Bartl , Mark Farrugia , Austin Iovoli , Oluwadamilola Temilade Oladeru , Joseph Miccio , Saif Aljabab , Simon Fung-Kee-Fung , Daphne A. Haas-Kogan , Anurag K. Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 575)
DOI
10.1200/JCO.2021.39.15_suppl.575
Abstract #
575
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).
First Author: Sahil Seth
Poster
2024 ASCO Annual Meeting
Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer.
First Author: Jeeyeon Lee
Poster
2023 ASCO Annual Meeting
Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.
First Author: Cheng Wang
Poster
2022 ASCO Annual Meeting
Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.
First Author: Sherene Loi